共 99 条
[1]
DiMasi JA(1995)Research and development costs for new drugs by therapeutic category Pharmaco Economics 7 152-169
[2]
Hansen RW(2010)Trends in risks associated with new drug development: success rates for investigational drugs Clinical Pharmacology & Therapeutics 87 272-277
[3]
Grabowski HC(2020)Empowering phase II clinical trials to reduce phase III failures Pharm Stat 19 178-186
[4]
Lasagna L(1988)Stopping rules and estimation problems in clinical trials Stat Med 7 1231-1242
[5]
DiMasi JA(2004)Conditional bias of point estimates following a group sequential test J Biopharm Stat 14 505-530
[6]
Feldman L(2012)Overestimation of the effect size in group sequential trials Clin Cancer Res 18 18,4872-18,4876
[7]
Seckler A(2010)Bias and trials stopped early for benefit Jama. 304 156-159
[8]
Wilson A(2013)Monitoring in clinical trials: benefit or bias? Theoretical Medicine and Bioethics 34 259-274
[9]
De Martini D(2012)Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer J Natl Cancer Inst 104 590-598
[10]
Hughes MD(2011)Trial watch: phase II failures: 2008–2010 Nat Rev Drug Discov 10 328-329